Project Grant F31CA295037
Award Date
9/20/25
Completion Date
9/19/27
Dollars Obligated
$138K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award, valued at $849,371.00, was issued on August 2, 2024 by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research aimed at "Hijacking Post-Translational Arginylation for Targeted Protein Degradation" at the Washington University in St. Louis. The key research activities include: Applying computational techniques to identify potential ATE1 binder hits for targeted protein degradation....
The National Cancer Institute (NCI) awarded Duke University a $387,702 R21 project grant (CFDA 93.396 Cancer Biology Research) to develop an automated bipartite algorithmic pipeline that leverages recent advancements in protein language modeling and co-complex databases to design peptide binders that can induce targeted protein degradation. This "ubiquibody" platform aims to enable the development of protein degraders for intractable cancer targets that are challenging to address...
This $380,540 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to decipher new principles of rapid proteostatic control and develop spatiotemporal lysosomal tools. The key research activities include: 1) defining novel protein substrates and motifs required for lysosomal delivery, 2) determining the functional impact of methyl-driven lysosomal proteolysis on...
This Project Grant award of $388,621 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of novel molecular designs with therapeutic potential. The key objectives are: Developing ligand-heterocycle conjugates as targeted RNA degraders with rapid kinetics and selectivity for cancer-associated G-quadruplexes. Engineering nucleic acid polymers with (thio)phosphoramidate backbones as biostable...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $218,886 to The Trustees of Columbia University in the City of New York to develop a new light-activated technology for targeted protein degradation in cancer cells. The project aims to optimize a photocatalytic system that can selectively degrade cancer proteins, such as the immune checkpoint receptor PD-1 and the oncogenic phosphatase SHP2, using deep red light to initiate targeted...
This $135,594 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award aims to develop novel pharmacological approaches to rewire oncogenic gene expression and induce apoptosis in cancer cells, with a focus on aggressive leukemias driven by mixed-lineage leukemia (MLL) gene translocations. The research will involve organic synthesis, pharmacological assays, chromatin mechanism studies, cellular model...
The National Institute of General Medical Sciences (NIGMS) awarded a $440,000 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to the Sloan-Kettering Institute for Cancer Research in New York. The 5-year grant, awarded on February 3, 2025, supports advanced research to decode the ubiquitin and autophagy signaling networks, which are essential cellular processes involved in proteome homeostasis. The research program combines expertise in quantitative mass spectrometry,...
This $103,948 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at elucidating the mechanisms driving T-cell dysfunction within the tumor microenvironment. The research plan includes two main components: Predoctoral research (Aim 1) to investigate how local amino acid availability limits effector function in tumor-infiltrating T-cells, including profiling the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $105,189 to the Regents of the University of Minnesota to advance research on inhibiting the structural dynamics of the APOBEC3A (A3A) and APOBEC3B (A3B) enzymes. The key objectives are to: Elucidate the structures of A3A and A3B when bound to viral inhibitors, such as ribonucleotide reductases from Macacine G-herpesvirus 11 and Kaposi Sarcoma-associated Herpesvirus, using...
The University of California, San Diego (UCSD) was awarded a $444,952 Project Grant by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to conduct research exploring the impact of base deaminase deregulation on precancer evolution. The 5-year grant, which commenced on December 1, 2024, aims to elucidate the relative roles of APOBEC3C and ADAR1 deaminases in driving the progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML). The research...